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Background: Although the co-burden of injection drug use and HIV is increasing in Africa, little is known about the
laboratory markers of injection drug use and anti-retroviral treatment (ART) in Kenyan injection drug users. This
study, therefore, aimed at determining the clinical chemistry profiles and identifying the key laboratory markers of
HIV infection during ART in injection heroin users (IHUs).
Methods: Clinical chemistry measurements were performed on serum samples collected from HIV-1 infected
ART-experienced (n = 22), naive (n = 16) and HIV-1 negative (n = 23) IHUs, and healthy controls (n = 15) from
Mombasa, coastal Kenya.
Results: HIV uninfected IHUs had lower alanine aminotransferase (ALT) levels (P = 0.023) as ART-exposed IHUs
exhibited lower albumin (P = 0.014) and higher AST to platelet index (APRI) (P < 0.0001). All IHUs presented with
lower aspartate aminotransferase to ALT values (P = 0.001) and higher C-reactive protein (CRP) levels (P = 0.002).
ART-naive IHUs had higher globulin levels (P = 0.013) while ART-experienced and naive IHUs had higher albumin to
total protein (P < 0.0001) and albumin to globulin (P < 0.0001) values. In addition, CD4+ T cells correlated with ALT
(ρ = −0.522, P = 0.011) and CRP (rho, ρ = 0.529, P = 0.011) in HIV negative and ART-experienced IHUs, respectively.
HIV-1 viral load correlated with albumin to globulin index in ART-experienced (ρ = −0.468, P = 0.037) and naive
(ρ = −0.554, P = 0.040) IHUs; and with albumin to total protein index (ρ = −0.554, P = 0.040) and globulin
(ρ = 0.570, P = 0.033) in ART-naive IHUs.
Conclusion: Absolute ALT, albumin, globulin, and CRP measurements in combination with APRI, AST to ALT,
albumin to total protein and albumin to globulin indices may be useful laboratory markers for screening IHUs for
initiating and monitoring treatment.
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Of the 14 million people who inject drugs worldwide, 1.64
million are HIV infected [1]. In addition, more than 40% of
new HIV infections in the world are attributed to injection
drug use [2]. HIV sero-prevalence rates among injection
drug users (IDUs) in Kenya are exceedingly high at 18%,
and at least, 17% of new HIV infections in the country are
linked to injection drug use [3]. Moreover, the rates of HIV
transmission in injection drug users in the country are
higher relative to the spread in the general population [4],* Correspondence: mugogwe@yahoo.com
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unless otherwise stated.suggesting that injection drugs and substance use are
important in promoting the spread of HIV in Kenya.
Although CD4+ T cell measurements are commonly
used in initiating and monitoring disease progression
and treatment in HIV-1 infected individuals [5], other
biomarkers may not be specific to HIV infection due to
concomitant illicit drug and poly-substance use among
injection drug users. Since, addictive drugs such as opi-
oids largely cause persistent immune stimulation indu-
cing chronic inflammation [6], while anti-retroviral
therapy cumulatively cause hepatotoxic injury [7], it is
likely that HIV-1 infected injection drug users progres-
sively develop intense inflammation and hepatotoxicitytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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atic functionality.
Injection drugs usually cause chronic liver degeneration
and marked derangements in hepatic synthetic functions
[6,8,9]. Elevated alanine aminotransferase (ALT), aspartate
aminotransferase (AST), globulin, aspartate aminotrans-
ferase to platelet index (APRI), and C-reactive protein
(CRP) levels are linked to injection drug use in both HIV
infected and uninfected individuals [10-14]. In contrast,
addictive heroin doses promote reductions in hepatic al-
bumin synthesis [15]. Taken together, these studies suggest
increased inflammatory-mediated hepatic derangements
in both HIV infected and uninfected injection drug users.
However, no studies to date have investigated clinical
chemistry profiles in injection heroin users, resident at
coastal Mombasa, Kenya. The identification of clinical
chemistry laboratory markers in this sub-population is of
great importance, since it can assist in the clinical manage-
ment of HIV in injection drug users. The current study,
therefore, examined clinical chemistry laboratory markers
in HIV-1 infected ART-experienced, naïve and HIV-1
non-infected injection heroin users, and healthy controls.
Methods
Study site and population
This cross-sectional clinical laboratory study was con-
ducted as part of a larger study investigating the microbio-
logical and immunological determinants of HIV infection
among adult injection drug users. The study was under-
taken at Bomu Hospital, a social enterprise facility in
Mombasa, a coastal region of Kenya. Mombasa has a large
injection drug using population of about 26,000, with her-
oin being the predominant injection drug [3]. Injection
drug users were recruited via respondent driven sampling,
snowball and makeshift outreach methods. Only individ-
uals (age ≥18 yrs.) exhibiting needle scars, reporting injec-
tion heroin use at least once in the previous month and
providing written informed consent were recruited into
the study. Healthy controls were recruited from among
HIV negative individuals presenting no evidence of illness
and history of drug use.
Sample collection
From each injection drug user and healthy control, 10 ml
of venous blood was collected. Of this, 5 ml was placed
into both the EDTA and plain BD vacutainer® tubes (BD,
Franklin Lakes, USA). The EDTA blood samples were
used immediately after collection for hematological mea-
surements and the enumeration of CD4+ T cells. Serum
was obtained from clotted blood after clot retraction and
centrifugation at 15,000 r.p.m for 10 minutes. The serum
samples were used for the determinations of clinical
chemistry analytes, HIV and hepatitis virus sero-testing,
and viral loads.HIV-1 diagnosis
HIV-1 testing was performed using rapid immunochroma-
tographic tests, Determine™ (Abbott Laboratories, Tokyo,
Japan) and Unigold™ (Trinity Biotech Plc, Bray, Ireland).
Study participants with positive results for both Determine
and Unigold were considered HIV infected based on the
Kenyan national HIV testing algorithm [16].
HBV and HCV testing
Sero-diagnosis for the presence of hepatitis B virus
(HBV) and hepatitis C virus (HCV) infections was per-
formed using the one-step HBV-5 panel, and anti-HCV
rapid diagnostic tests, respectively (Healthaw Medical
limited, Hangzhou, China). Serum samples were tested
for sero-reactivity against the HBV panel markers and
anti-HCV. HBsAg and anti-HCV reactive individuals were
considered sero-positive for HBV and/or HCV infection.
Clinical chemistry measurements
Direct clinical chemistry determinations were performed
for ALT, AST, gamma-glutamyl transpeptidase (GGT),
total protein, albumin, creatinine, urea, total cholesterol,
high density lipoprotein (HDL), CRP, phosphocreatine
kinase isoenzymes (CK-MB), and vitamin D using the
automated clinical chemistry analyzer (Roche COBAS®
6000, Lausanne, Switzerland). Globulin was calculated
by subtracting albumin concentrations from the total
protein levels and the albumin to globulin ratio >1 was
considered normal [17]. The reference values were based
on our laboratory established reference ranges. APRI
was determined as previously described [18], with AST
upper limit values from laboratory established reference
values (<37 U/L).
CD4+ T cell enumerations
Baseline CD4+ T cell counts were determined in an auto-
mated fashion using the BD FACSCalibur flow cytometer
(Becton-Dickinson™, Franklin Lakes, USA). Briefly, 5.0 μl
of EDTA blood samples were placed in a tube and RBC
lysis buffer added. After 5 minute incubation, the cells were
washed and fluorescent-tagged antibodies (anti-CD3, anti-
CD4, and anti-CD45) were added. The cells were incu-
bated for 30 minutes after which the samples were washed
and the CD4+ T cells enumerated on the flow cytometer.
HIV-1 viral load
HIV-1 viral loads were determined using the automated
Abbott m2000 System according to the manufacturer’s
instructions (Abbott Molecular Inc., Illinois, USA). Briefly,
RNA was extracted from 0.2 ml serum samples and
reverse-transcribed into cDNA. The cDNA was amplified
using HIV-1-specific and internal control primers. Fluor-
escence intensity of the HIV-1 probe was converted into
viral loads by the analyzer.
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Ethical approval for the study was obtained from Kenyatta
University Ethical Review Committee. Each participant
gave written informed consent prior to enrolment into the
study. Confidentiality of the study participant’s informa-
tion was ensured throughout the study by coding and
limiting accessibility of the study information. The
study participants benefited from free health education
on HIV, tuberculosis (TB), hepatitis B and C, sexually trans-
mitted infections, hygiene and nutrition. HIV-positive,
TB-positive and HIV-TB co-infected individuals were re-
ferred to the comprehensive care centers at Bomu Hospital
or the Coast General Provincial Hospital for treatment,
support and care.
Statistical analysis
Statistical analysis was conducted using IBM® SPSS Statis-
tics 19.0 (SPSS Inc. Chicago, USA). Continuous data (age,
and laboratory measures) summarized as medians (IQR)
and categorical data (gender, duration of injection, and
non-injection drugs) presented as proportions were tabu-
lated. Differences in the proportions were determined
using the chi-square tests. Statistical comparisons of the
continuous data across the study groups were performed
using non-parametric ANOVA (Kruskal Wallis) tests
followed by Bonferroni post-hoc corrections for multiple
comparisons. Spearman’s rank correlation tests were used
to determine the associations of clinical chemistry mea-
sures with CD4+ T cells and viral loads within the study
groups. A two-sided probability value <0.05 was consid-
ered statistically significant. Bonferroni correction for mul-
tiple comparisons were determined by dividing the
criterion P < 0.05 by the total number of the study groups
(P < 0.05/4 = P < 0.0125). The P < 0.0125 was then used for
statistical inferences following between-group Mann
Whitney U comparisons.
Results
Demographic and laboratory characteristics of the study
participants
The study population comprised both male (n = 39) and
female (n = 37) adult participants. These comprised of
HIV-1 infected ART-experienced (n = 22), naive (n = 16)
and HIV-1 non-infected (n = 23) injection heroin users, and
healthy controls (HC, n = 15). Table 1 summarizes the clin-
ical, laboratory and demographic characteristics of the
study participants. The ages of the study participants were
significantly different (P = 0.008). Additionally, between-
group analysis showed that the anti-retroviral treatment-
exposed injection heroin users were relatively older than
the healthy controls (P = 0.003). The proportions of male
and female participants were comparable across the study
groups (P = 0.351). Use of heroin as an injection drug was
common in all the injection heroin users (P = 0.999). Asnon-injection drugs; the use of bhang, rohypnol, cigarettes,
cocktail and alcohol were not significantly different among
the injection heroin users (P = 0.584, P = 0.338, P = 0.972,
P = 0.351 and P = 0.076, respectively). Across group ana-
lysis revealed a statistically significant difference in the
CD4+ T cell counts/μL (P < 0.0001) with the anti-retroviral
treatment-exposed (median, 301; IQR, 426) and treatment-
naive (median, 448; IQR, 337) groups presenting with
lower counts in comparison to HIV uninfected injection
heroin users (median, 986; IQR, 474) and healthy controls
(median, 755; IQR 463) (P < 0.0001 for all between-group
comparisons). The lower limit of HIV-1 viral load quantifi-
cation was 150 (2.18 log10) copies/ml of serum sample, and
median viral loads were comparable between both anti-
retroviral treatment-naive and anti-retroviral treatment-
exposed individuals (P = 0.163) (Table 1).
Clinical chemistry measurements
While across group analysis did not show significant
differences in the levels of phosphocreatine kinase iso-
enzymes (CK-MB) (P = 0.964), the levels of CRP differed
significantly across the study groups (P = 0.002). Subse-
quent post-hoc corrections revealed significantly higher
levels of CRP in anti-retroviral treatment-exposed (me-
dian, 4.0 mg/L; IQR, 7.8; P = 0.001), anti-retroviral
treatment-naive (median, 3.8 mg/L; IQR, 14.2; P <
0.0001) and in HIV-1 uninfected injection heroin users
(median, 6.1 mg/L; IQR, 8.4; P = 0.001) in comparison
to healthy controls (median, 0.7 mg/L; IQR, 0.9) signify-
ing the importance of CRP as an inflammation marker
of injection heroin use.
Additional analyses revealed statistical differences in
the activity of ALT among the study groups (P = 0.023).
Between-group tests showed lower ALT levels (U/L) in
HIV uninfected injection heroin users (median, 11.0;
IQR, 5.5) compared to healthy controls (median, 13.7;
IQR, 12.7; P = 0.005). However, across group analysis did
not reveal any differences in the activity of AST and
GGT among the study groups (P = 0.341 and P = 0.504,
respectively). Furthermore, no statistical differences were
found in the levels of total cholesterol, HDL cholesterol
and the ratio of total cholesterol to HDL cholesterol
across the study groups (P = 0.176, P = 0.828 and P =
0.117, respectively). The levels of total protein, creatinine,
urea and vitamin D were also comparable across the study
groups (P = 0.147, P = 0.840, P = 0.135 and P = 0.064, re-
spectively). Across group comparison of albumin levels
(g/L) further revealed that there were significant differ-
ences (P = 0.014), with a further between-group analyses
indicating that in anti-retroviral treatment-exposed injec-
tion heroin users, albumin levels (median, 41.1; IQR, 10.5)
were significantly lower compared to the healthy controls
(median, 48.0; IQR, 3.7; P < 0.0001). Further analysis indi-
cated that the levels of globulin (g/L) in the anti-retroviral
Table 1 Demographic, clinical and laboratory characteristics of the study participants
Characteristic









Age, yrs. 25.6 (8.7) 29.2 (7.1) 31.2 (5.9) 33.1 (8.5)a 0.008
Female/male, (%) 40.0/60.0 39.1/60.9 50.0/50.0 63.6/36.4 0.351
Injection drugs, n (%)
Heroin - 23 (100.0) 16 (100.0) 22 (100.0) 0.999
Diazepam - 0 (0.0) 3 (18.8) 2 (9.1) -
Duration of injection, n (%)
<1 yr. - 12 (52.2) 2 (12.5) 4 (18.2)
-1-3 yrs. - 7 (30.4) 9 (56.2) 5 (22.7)
>3 yrs. - 4 (17.4) 5 (31.3) 13 (59.1)
Non-injection drugs, n (%)
Bhang - 8 (34.8) 7 (43.8) 11 (50.0) 0.584
Brown sugar - 3 (13.1) 2 (12.5) 5 (22.7) -
Rohypnol - 12 (52.2) 9 (56.2) 16 (72.7) 0.338
Cigarettes - 18 (78.3) 12 (75.0) 17 (77.3) 0.972
Khat - 5 (21.7) 3 (18.8) 8 (36.4) -
Cocktail - 5 (21.7) 6 (37.5) 9 (40.9) 0.351
Alcohol - 8 (34.8) 9 (56.2) 15 (68.2) 0.076
CD4+ T cell count/μl 755 (463) 986 (474) 448 (337)a,b 301 (426)a,b <0.0001
Viral loads, copies/μl - - 13,470 (81,176) 150 (17,761) 0.163
Hepatitis B - 1 (4.3) 2 (12.5) 1 (4.5) -
Hepatitis C - 1 (4.3) 3 (18.8) 5 (22.7) -
Data shown are medians (IQR) unless indicated. HC, healthy controls. ART, anti-retroviral treatment. HIV-1, human immunodeficiency virus-1. IHUs, injection heroin
users. Brown sugar, crude heroin. Cocktail, cigarette and bhang mixture. Data analysis was conducted using chi-square for proportions; and Kruskal Wallis tests for
continuous data. Following the Kruskal Wallis tests, post-hoc Bonferroni corrections for multiple comparisons were performed based on the Mann Whitney
between-group tests (significant at P < 0.0125). aART-exposed and ART-naive IHUs vs. HC, P < 0.01. bART-exposed and ART-naive IHUs vs. HIV-1 uninfected IHUs,
P < 0.0001. Values in bold are statistically significant at P-values indicated.
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17.5) were higher compared to the healthy controls (me-
dian, 35.1; IQR, 11.1; P < 0.0001) and the HIV uninfected
injection heroin users (median, 36.6; IQR 10.4; P < 0.0001)
(Table 2).
AST, ALT, albumin, globulin and platelet ratios
Values for the AST to ALT ratio varied across the
groups (P = 0.001) and were higher in the anti-retroviral
treatment-exposed injection heroin users (median, 1.6;
IQR, 0.8; P < 0.01), anti-retroviral treatment-naive injec-
tion heroin users (median, 2.1; IQR, 0.9; P < 0.01) and
HIV negative injection heroin users (median, 1.8; IQR,
1.0; P < 0.01) relative to healthy controls (median, 1.1;
IQR, 0.7). In addition, at least a quarter of the anti-
retroviral treatment-exposed (27.3%), treatment-naive
(62.5%) and HIV negative injection heroin users (43.5%)
had AST to ALT ratio ≥2.0, indicating increased liver
damage in both HIV infected and uninfected injection
heroin users.Albumin to total protein ratio differed in the groups
(P < 0.0001) and were significantly lower in the anti-
retroviral treatment-exposed (median, 0.5; IQR, 0.1) and
treatment-naive (median, 0.4; IQR, 0.2) groups compared
to HIV negative injection heroin users (median, 0.6; IQR,
0.1) and healthy controls (median, 0.6; IQR, 0.1; P < 0.01
and P < 0.0001, respectively). Likewise, albumin to globu-
lin ratio varied in the study groups (P < 0.0001) such that
the anti-retroviral treatment-experienced (median, 1.0;
IQR, 0.5) and naive (median, 0.8; IQR, 0.6) individuals
had lower values in comparison to HIV negative group
(median, 1.5; IQR, 0.4; P = 0.002) and healthy controls
(median, 1.4; IQR, 0.3; P < 0.0001).
APRI differed significantly across the study groups
(P = 0.005) with the anti-retroviral treatment-exposed
group (median, 0.25; IQR, 0.20) having higher values
compared to the healthy controls (median, 0.14; IQR,
0.10; P = 0.001). Moreover, the frequency of moderate-
to-severe forms (i.e., APRI ≥ 0.5) of liver damage was
only noted in anti-retroviral treatment-exposed (18.2%)
Table 2 Clinical chemistry measurements of the study participants
Marker









CK-MB, U/L 18.0 (15.0) 17.0 (12.0) 17.5 (16.3) 18.0 (26.8) 0.946
CRP, mg/L 0.7 (0.9) 6.1 (8.4)a 3.8 (14.2)a 4.0 (7.8)a 0.002
CRP > 5.0 mg/L, n (%) 1 (6.7) 14 (60.9) 7 (43.8) 9 (40.9) -
ALT, U/L 13.7 (12.7) 11.0 (5.5)a 10.7 (5.4) 15.2 (11.0) 0.023
M > 40; F > 31, n (%) 2 (13.3) 0 (0.0) 1 (6.3) 2 (9.1) -
AST, U/L 19.5 (9.4) 21.7 (13.0) 22.4 (10.8) 24.9 (14.1) 0.341
AST/ALT 1.1 (0.7) 1.8 (1.0)a 2.1 (0.9)a 1.6 (0.8)a 0.001
AST/ALT ≥2.0, n (%) 0 (0.0) 10 (43.5) 10 (62.5) 6 (27.3) -
APRI 0.14 (0.10) 0.23 (0.20) 0.19 (0.10) 0.25 (0.20)a 0.005
APRI ≥0.5, n (%) 0 (0.0) 0 (0.0) 1 (6.3) 4 (18.2) -
GGT, U/L 23.0 (28.1) 27.0 (20.1) 27.5 (39.0) 41.5 (45.0) 0.504
TC, mmol/L 5.0 (1.5) 4.1 (2.0) 4.3 (1.9) 4.2 (1.6) 0.176
HDL, mmol/L 1.3 (0.5) 1.3 (0.7) 1.1 (0.7) 1.1 (0.8) 0.828
TC/HDL 3.5 (1.0) 3.3 (1.7) 3.9 (1.0) 4.0 (1.5) 0.117
ALB, g/L 48.0 (3.7) 45.3 (17.8) 41.5 (14.3) 41.1 (10.5)a 0.014
ALB <32.0 g/L, n (%) 0 (0.0) 1 (4.3) 2 (12.5) 2 (9.1) -
Total PROT, g/L 82.3 (15.9) 84.4 (22.8) 90.2 (27.7) 82.0 (27.8) 0.147
ALB/PROT 0.6 (0.1) 0.6 (0.1) 0.4 (0.2)a,b 0.5 (0.1)a,b <0.0001
GLB, g/L 35.1 (11.1) 36.6 (10.4) 51.2 (17.5)a,b 41.5 (32.9) 0.013
ALB/GLB 1.4 (0.3) 1.5 (0.4) 0.8 (0.6)a,b 1.0 (0.5)a,b <0.0001
ALB/GLB ≤1, n (%) 0 (0.0) 3 (13.0) 10 (62.5) 11 (50.0) -
Creatinine, μmol/L 80.0 (23.0) 72.0 (30.0) 75.0 (30.0) 81.0 (29.0) 0.840
Urea, mmol/L 3.5 (1.2) 2.9 (2.5) 2.8 (0.6) 3.0 (1.4) 0.135
Vitamin D, ng/ml 30.7 (8.2) 32.0 (15.0) 35.3 (23.3) 38.3 (13.3) 0.064
Data presented are medians (IQR) unless indicated. HC, healthy controls. ART, anti-retroviral treatment. HIV-1, human immunodeficiency virus-1. IHUs, injection
heroin users. CK-MB, phosphocreatine kinase isoenzymes. CRP, C-reactive protein. AST, aspartate aminotransferase. ALT, alanine aminotransferase. APRI, aspartate
to platelet index. GGT, gamma-glutamyl transpeptidase. TC, total cholesterol. HDL, high density lipoprotein cholesterol. PROT, protein. ALB, albumin. GLB, globulin.
Vitamin D3, 1,25-dihydroxyvitamin D. Data analysis was conducted using chi-square for proportions; and Kruskal Wallis tests for continuous data. Following the
Kruskal Wallis tests, post-hoc Bonferroni corrections for multiple comparisons were performed based on the Mann Whitney between-group tests (significant at
P < 0.0125). aART-exposed, ART-naive or HIV uninfected IHUs vs. HC, P < 0.01. bART-exposed and ART-naive IHUs vs. HIV-1 uninfected IHUs, P < 0.01. Values in bold
are statistically significant at P-values indicated.
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creased liver derangements in HIV infected injection
heroin users.
Correlation of the clinical chemistry markers with CD4+ T
cells and HIV viral loads
CD4+ T cells inversely correlated with ALT levels
(ρ = −0.522; P = 0.011; Figure 1A) in HIV uninfected injec-
tion heroin users and positively with the CRP levels
(ρ = 0.529; P = 0.011; Figure 1B) in HIV infected anti-
retroviral treatment-experienced injection heroin users.
HIV-1 viral loads inversely correlated with albumin to
globulin (ρ = −0.468, P = 0.037; Figure 2A) ratio in HIV
infected anti-retroviral treatment-exposed injection her-
oin users. In addition, the HIV-1 viral loads inverselycorrelated with albumin to globulin (ρ = −0.554; P = 0.040;
Figure 2B) and the albumin to total protein (ρ = −0.554;
P = 0.040; Figure 2C) values, and positively with globulin
(ρ = 0.570; P = 0.033; Figure 2D) in HIV infected anti-
retroviral treatment-naive injection heroin users.
Discussion
Clinical chemistry laboratory analysis constitutes a
key step in patient assessment for initiating and moni-
toring response to anti-retroviral treatment [5]. The
reliability and accuracy of clinical chemistry analytes,
however, is confounded by complex interaction be-
tween injection drug use and anti-retroviral drugs.
Therefore, this cross-sectional clinical laboratory
study determined the clinical chemistry markers in
BA
Figure 1 Correlations of CD4+ T cell counts with alanine aminotransferase and C-reactive protein. Correlations of the CD4+ T cells with
alanine aminotransferase and C-reactive protein levels were determined using the Spearman’s rank correlation test. (A) Correlation between CD4+ T
cells and alanine aminotransferase in HIV uninfected injection heroin users (n = 23). (B) Correlation between CD4+ T cells and square root of
the C-reactive protein (SQRT CRP) in HIV infected ART-exposed injection heroin users (n = 22).
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from coastal Kenya.
Absolute albumin levels and albumin to total protein
ratio reductions observed in the HIV-1 infected injection
drug users are indications of derangements in protein
metabolism. The decreases in the albumin levels can be
attributed to low dietary intake of proteins that is linked
to low synthesis of albumin [19], a feature of malnutri-
tion that is frequently observed among injection drug
users presenting with and without HIV infection [20]. It
is also possible that suppression of albumin results from
inhibition of hepatic synthesis at abusive doses of heroinA
C
Figure 2 Correlations of HIV-1 viral load with albumin to globulin, alb
loads with albumin to globulin, albumin to total protein and globulin levels w
between HIV-1 viral load and albumin to globulin index in anti-retroviral treat
HIV-1 viral load and albumin to globulin index in anti-retroviral treatment
viral load and albumin to total protein index in anti-retroviral treatment-n
load and calculated globulin in anti-retroviral treatment-naive injection he[15]. In addition, opioid-induced hepatotoxicities and
inflammatory-mediated hepatic damage cause reduced
hepatic synthetic functions [15,21]. Thus, findings pre-
sented here suggest that injection heroin use among
HIV-infected individuals promote increased reductions
in the albumin levels and marked alterations in the albu-
min to total protein ratio.
The inverse associations of HIV viral load and albumin
to total protein and albumin to globulin indices in the
anti-retroviral-naive injection heroin users signify dis-
ease progression but during treatment the albumin to
globulin ratio is inverted indicating reductions in theB
D
umin to total protein and globulin. Correlations of the HIV-1 viral
ere determined using the Spearman’s rank correlation test. (A) Correlation
ment-exposed injection heroin users (n = 22). (B) Correlation between
-naive injection heroin users (n = 16). (C) Correlation between HIV-1
aive injection heroin users (n = 16). (D) Correlation between HIV-1 viral
roin users (n = 16).
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in part, consistent with clinical studies in HIV infected
patients commencing highly active anti-retroviral ther-
apy showing that hypoalbuminaemia is associated with
morbidity and mortality [22,23]. Therefore, reduced al-
bumin and low albumin to total protein ratio are im-
portant laboratory measures in injection heroin users
that can be utilized as important surrogates for screen-
ing and for initiating and monitoring of anti-retroviral
treatment in HIV infected injection heroin users.
In contrast to previous studies, a higher globulin level
was found in the HIV infected injection heroin users
naive for anti-retroviral treatment [17]. This finding sug-
gests that hyperglobulinaemia is an important laboratory
marker of HIV infected patients injecting illicit drugs.
Hyperglobulinaemia characterizes B cell dysfunction
during primary HIV infections and persisting into
chronic infections [24]. The lower median albumin to
globulin values in the presence of higher proportions of
ratios ≤1.0, and the correlations of HIV viral loads with
globulin in the anti-retroviral treatment-naive individ-
uals, further corroborate increased derangements in B
cell functions in both HIV infected and uninfected injec-
tion heroin users. The findings of the current study also
parallel studies showing elevated globulin and the albu-
min to globulin ratio in Australian drug addicts [12]. In
addition, elevations in total IgM and IgG, specific anti-
morphine IgM, and cross-reactive IgM auto-antibodies
were recorded in HIV infected and uninfected opioid
users [25-27]. Hence, it appears heroin-induced anti-
bodies promote inflammation leading to liver damage in
injection users. Elevated globulin with concomitant
lower albumin to globulin ratio may thus be a useful
biomarker for clinical laboratory assessment of HIV in-
fected and uninfected injection heroin users.
Reduced absolute ALT levels found in the HIV sero-
negative injection heroin users, indicate reduced hepatic
functionality. However, the higher AST to ALT ratio and
proportions of AST to ALT ratio ≥2.0 in the HIV sero-
negative and infected injection heroin users naive or on
anti-retroviral treatment, suggest synergistic heroin and
anti-retroviral drug-induced hepatic inflammation.
These results are similar to observations showing that
the AST to ALT ratio is a better measure of liver enzyme
activity [28]. In addition, the results are, in part, sup-
ported by the elevated AST, AST to ALT ratios, and
higher proportions of ALT observed in patients on anti-
retroviral treatment [10-12]. Since a large number of the
injection heroin users in the present study were con-
comitantly consuming alcohol and khat, it is possible
that these non-injection substances synergistically pro-
mote the alterations in the ALT levels [10,29]. Import-
antly, the inverse correlations of absolute ALT levels and
the CD4+ T cell counts in the HIV sero-negativeinjection heroin users, suggests that the CD4+ T cell
count can also be utilized as a surrogate marker of liver
function in the management of HIV negative heroin
users.
The greater magnitude APRI median values and pro-
portions ≥0.5 in the HIV infected injection heroin users
on anti-retroviral treatment, suggests, that APRI is a bet-
ter screening indicator of heroin and anti-retroviral
treatment in this population. This observation is, in part,
parallel to the time-dependent increases and prognostic
value of APRI among HIV and hepatitis C co-infected
patients undergoing anti-retroviral treatment [7], and
studies in injection drug users showing the utility of
APRI in predicting hepatic fibrosis [30]. It is, therefore,
likely that increased hepatotoxicity in HIV patients on
anti-retroviral treatment results from the synergistic ef-
fect of anti-retroviral drugs, heroin and poly-substance
consumption. Hence, APRI and proportions of APRI ≥0.5
are important measures for evaluating the degree of
hepatoxicity in HIV infected injection heroin users
undergoing anti-retroviral treatment.
Elevations of the C-reactive protein in all the study
groups of injection heroin users is similar to previous
studies showing elevated C-reactive protein in Australian
drug addicts [12], and higher C-reactive protein levels in
buprenorphine injection users in Singapore [31]. Higher
levels and proportions of individuals of this acute phase
protein in both HIV infected and uninfected injection
heroin users in the present study are indicative of in-
creased liver synthesis following consumption of the
illicit drugs, infection and cytokine release [32]. In
addition, the increases indicate heightened liver damage
through illicit drug- and anti-retroviral treatment-
mediated necrosis, apoptosis, and immune mechanisms.
Of significance are analyses showing positive correlations
between the C-reactive protein levels and the CD4+ T
cell count in injection heroin users on anti-retroviral
treatment. This result may reflect development of im-
mune reconstitution inflammatory syndrome (IRIS) in
the injection heroin users on anti-retroviral treatment
resulting from poor adherence and illicit drug use. Con-
sistent with this hypothesis, previous studies illustrated
a link between IRIS and low adherence to anti-retroviral
therapy, alcohol use, and low suppression of viral load
among South African adults initiating anti-retroviral
therapy [33]. Implications of this observation include
utilization of the C-reactive protein in assessing immune
reconstitution following initiation of anti-retroviral treat-
ment in injection heroin users.
Our results clearly show high rates of poly-drug use
among injection heroin users in Mombasa. It is highly
likely that the complex interactions of opioids and/or ac-
tive compounds in bhang (Δ9-tetrahydrocannabinol), ciga-
rettes (nicotine), rohypnol (benzodiazepines), alcohol, khat
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rence of drug dependence and adverse events. With
regards to clinical chemistry profiles, such complex inter-
actions induce hepatic metabolic derangements leading to
toxicity and altered profiles of clinical chemistry markers.
Consistent with these propositions, previous studies
among drug users showed that interactions between opi-
oids and benzodiazepines or alcohol increase occurrence
of adverse events, overdose and death [34], as nicotine in-
crease rates of opioid consumption [35]. In addition, drugs
of abuse (alcohol, opioids, benzodiazepines, marijuana,
and nicotine) reduce the efficacy of anti-retroviral drugs
leading to toxicity, treatment failure and high viral loads
[36]. Taken together, poly-drug use appears to promote
toxicity leading to altered clinical chemistry profiles in
both HIV-1 infected and uninfected injection drug users.
While a prospective design would have been important
in examining the utility of clinical chemistry markers, in
response to drug rehabilitation and HIV treatment, this
cross-sectional study provides the first baseline informa-
tion for screening of injection drug users for initiating
and monitoring anti-retroviral treatments in Kenya. Al-
though recruitment into this study was based on self-
reported injection heroin use, it is possible that the study
participants were also using other opioids, hence the
need to carry out toxicological analyses to provide add-
itional insights into the complex interactions between
injection drugs and anti-retroviral treatment. These col-
lectively can be linked to clinical laboratory markers and
patient prognosis in a prospective approach.
Conclusions
This study provides further evidence that chronic inflam-
mation in HIV infected and uninfected injection heroin
users is characterized by derangements in hepatic synthetic
functions. Our data suggest that injection heroin, HIV
infection and anti-retroviral treatment differentially alter
ALT; albumin; APRI and AST to ALT, albumin to total
protein and albumin to globulin indices; C-reactive protein;
and globulin in injection drug users.
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